東陽光藥：中期報告2020.pdf

1、Contents 目錄2Financial Highlights財務摘要3Corporate Profile公司簡介6Management Discussion and Analysis管理層討論及分析57Corporate Governance and Other Information企業管治及其他資料71Review Report審閱報告73Consolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他全面收益表74Consolidated Statement of Financial Posi

2、tion綜合財務狀況表76Consolidated Statement of Changes in Equity綜合權益變動表78Condensed Consolidated Cash Flow Statement簡明綜合現金流量表79Notes to the Unaudited Interim Financial Reports未經審核中期財務報告附註113Corporate Information公司資料YICHANG HEC CHANGJIANG PHARMACEUTICAL CO.,LTD./INTERIM REPORT 20202Financial Highlights財務摘要(RM

3、B000)（人民幣千元）Six months ended 30 June 2020截至二零二零年六月三十日止六個月Six months ended 30 June 2019截至二零一九年六月三十日止六個月Year ended 31 December截至十二月三十一日止年度 2019201820172016二零一九年二零一八年二零一七年二零一六年 Revenue營業額2,083,7053,071,2596,224,024 2,510,4761,601,567941,504Gross profit毛利1,730,8412,620,8205,302,202 2,111,6671,321,151727

4、,270Profit from operations經營溢利880,9001,257,0672,473,556 1,103,742752,484460,299Profit before taxation除稅前溢利757,8361,172,6342,269,053 1,102,324748,195453,066Profit attributable to equity shareholders of the Company本公司權益股東應佔溢利617,508968,4241,918,709 942,536647,101380,597Earnings per share (RMB cent)每股盈

5、利（人民幣分）Basic 基本7010942720914384 Diluted 攤薄6310941020914384Total assets總資產10,460,0059,131,2519,912,3394,560,9403,775,9752,831,109Total liabilities總負債5,486,1334,865,6885,289,184882,012715,389373,302Net assets淨資產4,973,8724,265,5634,623,1553,678,9283,060,5862,457,807Profitability盈利能力Gross profit margin毛

6、利率83.1%85.3%85.2%84.1%82.5%77.2%Operating profit margin經營溢利率42.3%40.9%39.7%50.4%47.0%48.9%Net profit margin淨利潤率29.6%31.3%30.6%35.9%39.1%40.4%3Corporate Profile公司簡介中期報告2020 /宜昌東陽光長江藥業股份有限公司宜昌東陽光長江藥業股份有限公司（以下簡稱 本公司或 東陽光藥，連同其附屬公司統稱 本集團）是一家專注於抗病毒、內分泌與代謝以及心血管等疾病治療領域進行醫藥產品研究及開發（研發）、生產及銷售的製藥企業，是東陽光集團旗下的國內製